The Tyrosine Protein Kinase Lyn pipeline drugs market research report outlays comprehensive information on the Tyrosine Protein Kinase Lyn targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Tyrosine Protein Kinase Lyn pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Respiratory, Oncology, Central Nervous System, and Gastrointestinal which include the indications Idiopathic Pulmonary Fibrosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Oncology, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Metabolic Dysfunction-Associated Steatohepatitis (MASH), and Systemic Mastocytosis. It also reviews key players involved in Tyrosine Protein Kinase Lyn targeted therapeutics development with respective active and dormant or discontinued products.
The Tyrosine Protein Kinase Lyn pipeline targets constitutes close to 13 molecules. Out of which, approximately 11 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, and Preclinical stages are 1, 1, 1, 2, 3, and 3 respectively. Similarly, the universities portfolio in Discovery comprises 2 molecule.
Tyrosine Protein Kinase Lyn overview
Tyrosine protein kinase Lyn (LYN) transmits signals from cell surface receptors and plays an important role in the regulation of innate and adaptive immune responses, hematopoiesis, responses to growth factors and cytokines, integrin signaling, but also responses to DNA damage and genotoxic agents. LYN is important for immune self-tolerance and plays an important role in the regulation of B-cell differentiation, proliferation, survival, and apoptosis.
For a complete picture of Tyrosine Protein Kinase Lyn’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
